Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
58results about How to "Induce expression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibodies that bind human cd27 and uses thereof
InactiveUS20120213771A1Enhance immune responseInduce expressionAnimal cellsBacteriaMonoclonal antibodyDiagnostic methods
Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Owner:CELLDEX THERAPEUTICS INC
Antibodies that bind human CD27 and uses thereof
ActiveUS9169325B2Enhance immune responseInduce expressionAntibacterial agentsSenses disorderMonoclonal antibodyDiagnostic methods
Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Owner:CELLDEX THERAPEUTICS INC
Tunable genetic switch for regulating gene expression
ActiveUS20100175141A1Eliminating background expressionInhibit expressionBiocideGenetic material ingredientsDiseaseBinding site
The present invention relates generally the field of genetics, in particular methods, compositions and systems for controlling the inducible expression of transgenes, while eliminating background expression of transgene expression. The present invention relates to methods of use of the compositions and systems as disclosed herein for controlling the inducible expression of transgenes while eliminating background expression of transgene expression, such as use in, for example, the in generation of transgenic animals, use in therapeutic application and use in assays. In some embodiments, the present invention relates to a system of controlled expression of RNAi molecules which target binding sites in the untranslated regions of transgene, thereby the expression of the transgene is modulated and leakiness is reduced. The compositions and methods of the present invention can be used to for therapy, prophylaxis, research and diagnostics in diseases and disorders which afflict mammalian species, generation of transgenic animals, in the study of biological processes as well as for enhance performance of agricultural crops.
Owner:TRUSTEES OF BOSTON UNIV
Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
InactiveUS20060135612A1Improve survivalAmeliorated histone hypoacetylationBiocideAnimal repellantsAmyotrophic lateral sclerosisNeuro-degenerative disease
A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), includes administering a histone deacetylase (HDAC) inhibitor in a subject in need thereof. The HDAC inhibitor includes sodium butyrate or sodium phenylbutyrate.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Light-Emitting Diode and Method For Fabrication Thereof
InactiveUS20080315176A1Improve pressure resistanceOutstanding resistanceSolid-state devicesSemiconductor/solid-state device manufacturingHigh resistanceP–n junction
A light-emitting diode includes a substrate, a compound semiconductor layer including a p-n junction-type light-emitting part formed on the substrate, an electric conductor disposed on the compound semiconductor layer and formed of an electrically conductive material optically transparent to the light emitted from the light-emitting part and a high resistance layer possessing higher resistance than the electric conductor and provided in the middle between the compound semiconductor layer and the electric conductor. In the configuration of a light-emitting diode lamp, the electric conductor and the electrode disposed on the semiconductor layer on the side opposite to the electric conductor across the light-emitting layer are made to assume an equal electric potential by means of wire bonding. The light-emitting diode abounds in luminance and excels in electrostatic breakdown voltage.
Owner:SHOWA DENKO KK
Methods and Compositions for Unsilencing Imprinted Genes
ActiveUS20130317018A1Induce expressionBiocideCarbohydrate active ingredientsTopoisomerase inhibitorGenome
The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Antioxidant enhancement of therapy for hyperproliferative conditions
InactiveUS7071158B2Good curative effectHigh cytotoxic activityBiocidePeptide/protein ingredientsAntioxidantCytotoxicity
A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.
Owner:SALUTRIA PHARMACEUTICALS LLC
Light-emitting diode and method for fabrication thereof
InactiveUS7863630B2Increase resistanceSimple structureSolid-state devicesSemiconductor/solid-state device manufacturingHigh resistanceP–n junction
Owner:RESONAC HOLDINGS CORPORATION
Methods for treating cancer using combination therapy
The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof.
Owner:UNIV OF COLORADO THE REGENTS OF
Methods and compositions for treatment of obesity-related diseases
InactiveUS20110065756A1Increase insulin sensitivityReduce hypertensionBiocideMetabolism disorderHypertension medicationsAnti hypertension
The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g., edema, congestive heart failure) and / or in need of synergistic anti-inflammatory, anti-hypertensive, and anti-diabetic effect.
Owner:NORTHWESTERN UNIV +1
Gold optimized CAR T-cells
ActiveUS10323249B2Reduced half-lifeReduces GAPDH bindingImmunoglobulin superfamilyVectorsAntigen receptorsTransgene
Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.
Owner:CHIMERA BIOENG INC
Restoring vascular function
InactiveUS20060172943A1Modulate activityPromote cell migrationPeptide/protein ingredientsUnicellular algaeVascular diseaseMedicine
The invention relates to Tenascin-C and peptides that bind thereto. According to the invention, Tenascin-C or peptides and antibodies that bind thereto can be used to treat or prevent vascular diseases, either alone or in combination with therapeutic agents or cells that have cardioplastic potential.
Owner:CORNELL RES FOUNDATION INC
Fibrocyte-based vaccine formulations
InactiveUS20040022774A1Conveniently separatedIncrease the number ofAntibacterial agentsBiocideAntigenTumor cells
There is disclosed a fibrocyte-based vaccine formulations made from isolated fibrocytes. There is further disclosed a method for establishing an immune response against a specific antigen by administering a fibrocyte-based vaccine formulation, such as one made by pulsing fibrocytes in culture with the antigen peptide or protein, or by fusing tumor cells (whole cells or membrane fragments thereof) with fibrocytes.
Owner:RICE GLENN C +1
Mesenchymal stem cell therapy for spinal muscular atrophy
InactiveUS20190136192A1Improve expression levelIncrease the number ofAntipyreticAnalgesicsDiseaseMesenchymal stem cell
Disclosed are means, methods and compositions of matter useful for treatment of spinal muscular atrophy. In one embodiment, stem cells of the mesenchymal type are modified to enhance anti-inflammatory and regenerative potential in a manner to prevent disease, inhibit progression and / or reverse existing disease. In other embodiments combinations of mesenchymal stem cells together with extracts and / or products derived from said mesenchymal stem cells are administered for prevention, inhibition of progression and / or reversion of spinal muscular atrophy.
Owner:CELL MEDICINE
Gold Optimized CAR T-cells
ActiveUS20180057822A1Reduced half-lifeReduces GAPDH bindingImmunoglobulin superfamilyVectorsAntigen receptorsTransgene
Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.
Owner:CHIMERA BIOENG INC
Nucleotide sequences involved in disease resistance
InactiveUS20060253924A1Reduce riskNo wounding of the plantBacteriaImmunoglobulinsBiotechnologyNucleotide
Method for the identification and isolation of expressed nucleic acid sequences that are associated with disease resistance of a plant against a plant pathogen, isolated nucleic acid molecules and variants and / or homologues thereof, constructs, plants and polypeptides encoded by said nucleotide sequences and the use of these sequences in the development of resistance in plants against pathogens.
Owner:KEYGENE NV
Tunable genetic switch for regulating gene expression
ActiveUS9388425B2Eliminating background expressionInhibit expressionBiocideGenetic material ingredientsDiseaseBinding site
Owner:TRUSTEES OF BOSTON UNIV
Composition of mesenchymal stem cells
InactiveUS20160129043A1Reduce wrinklesSuppress peripheral blood lymphocyte proliferationCell dissociation methodsBiocideNeurulationGerm layer
This invention relates in general to a mesenchymal stem cell (MSC) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells. More particularly, this invention relates to the isolation and applications of the neural crest derived gingiva mesenchymal stem cells and / or mesoderm derived gingiva mesenchymal stem cells. This invention also relates to a composition comprising a neural crest derived gingiva mesenchymal stem cell and / or a mesoderm derived gingiva mesenchymal stem cell. This composition may be used for wound healing and / or in the treatment of inflammatory and / or autoimmune diseases.
Owner:UNIV OF SOUTHERN CALIFORNIA
OsCc1 promoter and methods of transforming monocot plants using the same
InactiveUS6958434B2Easy to useInduce expressionSugar derivativesOther foreign material introduction processesPlasmidAgronomy
Owner:MYONGJI UNIV IND & ACAD COOPERATION FOUND
Cancer therapy
The present invention relates to methods of inducing expression of an epigenetically silenced gene, RASSF1A, in cells, particularly human cells, such as cancer cells. It also relates to methods of treating an individual, prophylactically or therapeutically, for cancer in which RASSF1A is epigenetically silenced.
Owner:GEORGETOWN UNIV
Compositions and methods for detecting and treating colorectal cancer
ActiveUS20150212088A1Affect colon cancer patient outcomeIncreased formationOrganic active ingredientsMicrobiological testing/measurementCytokineSUZ12
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and / or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.
Owner:RGT UNIV OF MICHIGAN
Influencing angiogenesis using CD66a
InactiveUS20060058257A1Induce expressionInhibit expressionGenetic material ingredientsAntibody ingredientsMedicineAngiogenesis growth factor
The invention relates to a method of influencing angiogenesis by administering a of a compound in a pharmaceutically compatible carrier selected from the group consisting of (i) CD66a, a CD66a variant, CD66a fragments or CD66a-derived glycostructures, or CD66a ligands, or (ii) of anti-CD66a specific antibodies and anti-sense oligonucleotides.
Owner:WAGENER +2
Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC
InactiveUS9371295B2Increase percentageInduce expressionOrganic active ingredientsOrganic chemistryHemoglobinopathyHistone deacetylase
Owner:IRBM SCI PARK +1
Methods and compositions for evaluating cell function in sensory neurons
InactiveUS20060211021A1Reduce expressionIncrease expressionCompounds screening/testingVirusesA domainSensory neuron
Methods and compositions are provided for determining whether target, e.g., an endogenous or novel (non-endogenous), nucleic acid sequence of a neuronal cell is involved in sensory function. In practicing the subject methods, a neuronal cell selective vector including a modulating domain for a neuronal cell nucleic acid sequence, optionally having a domain encoding a directly detectable product, is administered to an animal. Sensory function in harvested neuronal cells is then evaluated to determine whether the target nucleic acid sequence is involved in sensory function. Also provided are compositions, kits, and systems for practicing the subject methods.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Modified retinal pigment epithelial cells for cell transplantation
InactiveUS20050019909A1Enhance abilityInduce expressionBiocideGenetic material ingredientsRetinal pigment epithelial cellBiology
A transplantable composition comprises retinal pigment epithelium cells modified to induce expression and / or secretion of a therapeutic molecule, that can be used to prevent and / or treat disease.
Owner:THE CLEVELAND CLINIC FOUND
Assay for Cytochrome P450 Isoforms 3A4 and 3A5
InactiveUS20080145886A1Rapid and sensitiveInduce expressionCompound screeningApoptosis detectionAssayAnalyte
A rapid and sensitive radiometric assay for assessing the activity of cytochrome P450 (CYP) 3A4 / 5 and the potential of an analyte to inhibit CYP3A4 / 5 activity or induce CYP3A4 / 5 expression is described. All the steps of the assay, including incubations, product separation, and radioactivity counting are preferably performed in a multiwell format, which can be automated.
Owner:IST DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI
MGAL: A GAL Gene Switch-Based Suite of Methods for Protein Analyses and Protein Expression in Multicellular Organisms and Cells Therefrom
InactiveUS20080249045A1Reduce the amount requiredInduce expressionMicrobiological testing/measurementGenetic material ingredientsAgonistRegulator gene
Owner:PENN STATE RES FOUND
Method for regulating agrobacterium-mediated transformation
InactiveUS20090263902A1Induce expressionBacteriaOther foreign material introduction processesGene expressionBiology
A method for regulating expression of a virulence gene of Agrobacterium is described. The method comprises the steps of stimulating cereal cells, such as sorghum, so as to produce an active, typically phenolic, compound and exposing the Agrobacterium to this compound. The compound induces expression of the virulence gene of the Agrobacterium, effecting T-DNA transfer from the Agrobacterium to the cereal cells, which are thereby transformed.
Owner:CSIR +1
Cell culture media for differentiation of stem cells into hepatocytes
PendingUS20200199528A1Enhance maturationHigh throughputDrug screeningCulture processCell culture mediaMolecular biology
The invention relates to methods and media for inducing or maintaining a mature hepatocyte phenotype in a cell, the method comprising the step of cultivation cells in a cell culture medium comprising at least 10 mg amino acids / ml medium, wherein at least 50% (w / w) of the concentration of said amino acids in said medium is provided by one up to five amino acids and, with the proviso that said one up to five amino acids is not one of Thr, Tyr, Cys, Met, Arg and His.
Owner:KATHOLIEKE UNIV LEUVEN
Method for regulating agrobacterium-mediated transformation
InactiveUS8143484B2Induce expressionOther foreign material introduction processesFermentationSorghumBiology
A method for regulating expression of a virulence gene of Agrobacterium is described. The method comprises the steps of stimulating cereal cells, such as sorghum, so as to produce an active, typically phenolic, compound and exposing the Agrobacterium to this compound. The compound induces expression of the virulence gene of the Agrobacterium, effecting T-DNA transfer from the Agrobacterium to the cereal cells, which are thereby transformed.
Owner:CSIR +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com